XXXX may induce cytokine-release syndrome in @entity14 @entity1 .

@entity901 @entity1 @entity650 @entity390 @entity5 @entity310 @entity294 @entity619 @entity134 @entity14 @entity490 @entity551 @entity902
INTRODUCTION: @entity901 , a third-generation @entity902 analogue, is a novel compound with proven anti- @entity5 activity in @entity14 . Moreover, @entity901 appears to be relatively well tolerated and easy to handle, even on an outpatient basis. @entity1 AND METHODS: Five advanced @entity14 @entity1 treated with @entity901 -based chemotherapy developed, after the end of @entity901 infusion, similar idiosyncratic reactions characterized by chills, high fever, @entity551 , @entity490 , @entity390 and often @entity294 . Venous blood for @entity650 and @entity310 assessment was drawn just after the beginning of the reaction and 15 and 30 minutes later. After drawing the third venous sample, intravenous @entity619 (8 mg) was administered and the drawing of other two venous samples was performed (180 and 360 minutes after the beginning of the reaction). RESULTS: @entity310 and @entity650 serum concentrations significantly decreased after @entity134 therapy administration. The decrease of @entity310 and @entity650 levels went along with the clinical complete regression of symptoms and signs in all the 5 @entity1 . No statistically significant correlation was found between other laboratory parameters and basal cytokine levels or cytokine decrease after @entity134 therapy. DISCUSSION: Our results clearly show that that idiosyncratic reaction observed in @entity14 @entity1 after @entity901 infusion may be due to a massive release of cytokines such as @entity310 and @entity650 . Symptom regression following @entity134 therapy administration went along with significant decrease of cytokines levels, confirming that @entity310 and @entity650 play a role in the pathogenesis of this reaction.
